[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346545-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346545-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","microbiomegenome-crosstalk-in-colorectal-cancer-colibactin-signatures-and-fusobacterium-nucleatum-in-epidemiology-driver-selection-and-translation","Microbiome–Genome Crosstalk in Colorectal Cancer - Colibactin Signatures and Fusobacterium nucleatum in Epidemiology, Driver Selection, and Translation","","Colibactin, a genotoxin produced by pks+ E. coli, leaves highly specific mutational signatures SBS88 and ID18 in colorectal cancer and even in normal colonic crypts. Population-scale analyses show enrichment in early-onset disease, geographic variation, and early imprinting during tumor evolution, where probabilistic attribution links colibactin to a measurable share of APC driver mutations. Fusobacterium nucleatum adds clade-specific effects on tumor ecology and therapy response, supporting both chemoresistance and anti-PD-1 sensitization in MSS CRC. Mechanistic evidence and analytic standards for signature detection (WGS/WES, single-sample fitting, low-count limits) are connected to translational routes including noninvasive stool metagenomics and risk stratification. Microbial-targeted interventions are discussed.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/microbiomegenome-crosstalk-in-colorectal-cancer-colibactin-signatures-and-fusobacterium-nucleatum-in-epidemiology-driver-selection-and-translation/346545/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/microbiomegenome-crosstalk-in-colorectal-cancer-colibactin-signatures-and-fusobacterium-nucleatum-in-epidemiology-driver-selection-and-translation/346545.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What mutational signatures are linked to colibactin in colorectal cancer?","Question",{"text":63,"@type":64},"Colibactin is associated with the SBS88 single-base substitution signature and the ID18 insertion/deletion signature, detected in colorectal cancer and even normal colonic crypts.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does Fusobacterium nucleatum influence colorectal tumor behavior and treatment response?",{"text":68,"@type":64},"Fusobacterium nucleatum exerts clade-specific effects on tumor ecology and therapy response, with evidence for both chemoresistance and sensitization to anti-PD-1 in microsatellite stable (MSS) colorectal cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"What analysis approaches and constraints are described for detecting these signatures?",{"text":72,"@type":64},"The article outlines analytic standards for signature detection using whole-genome sequencing (WGS) or whole-exome sequencing (WES), single-sample fitting, and stated limits when mutation counts are low.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346545,1790811317,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Review  \nMicrobiome–Genome Crosstalk in Colorectal Cancer: Colibactin Signatures and Fusobacterium nucleatum in Epidemiology, Driver Selection, and Translation  \nSungwon Jung 1,2  \nAcademic Editor: Cristina Peña  \nReceived: 31 December 2025  \nRevised: 6 February 2026  \nAccepted: 10 February 2026  \nPublished: 23 February 2026  \nCopyright: © 2026 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Genome Medicine and Science, Gachon University College of Medicine, Incheon 21565, Republic of Korea; [sjung@gachon.ac.kr](sjung@gachon.ac.kr); Tel.: +82-32-458-2740  \n2 Gachon Institute of Genome Medicine and Science, Gachon University Gil Medical Center, Incheon 21565, Republic of Korea  \nAbstract  \nColibactin, a genotoxin produced by pks+ E. coli, imprints highly specific mutational signatures SBS88 and ID18 in colorectal cancer (CRC) and even in normal colonic crypts. Population-scale analyses show these signatures are enriched in early-onset CRC, vary geographically, and are imprinted early during tumor evolution, where probabilistic attribution indicates that colibactin contributes to a measurable fraction of APC driver mutations in colibactin-positive cancers. Beyond colibactin, Fusobacterium nucleatum exerts clade-specific effects on tumor ecology and therapy response, with data supporting both chemoresistance and sensitization to anti-PD-1 in microsatellite stable (MSS) CRC. This article covers mechanistic, genomic, and molecular epidemiology evidence, outlines analytic standards for signature detection (whole-genome sequencing (WGS)/whole-exome sequencing (WES), single-sample fitting, and limits at low mutation counts), and charts translational paths spanning noninvasive screening (stool metagenomics + mutational signatures in tissue/circulating tumor DNA (ctDNA)), risk stratification, and microbialtargeted interventions (antibiotics, phages, ClbP inhibitors) . Framing microbiome–genome crosstalk as a tractable axis enables testable clinical hypotheses for precision oncology.  \nKeywords: colibactin; mutational signatures; microbiome–genome crosstalk; colorectal cancer; Fusobacterium nucleatum; molecular epidemiology; precision oncology  \n1. Introduction  \nCRC remains a major global health burden as the third-most diagnosed malignancy and the second leading cause of cancer-related mortality worldwide [1] . In 2020 alone, over 1.9 million new CRC cases were diagnosed and about 935,000 deaths occurred. While incidence and mortality have stabilized or declined in some high-resource regions due to screening and risk factor modifications, and an alarming trend has emerged: CRC rates are rising among adults under 50 years of age across diverse countries [2] . Recent analyses of cancer registry data from 50 countries found that early-onset CRC incidence (ages 25–49) is increasing in 27 of them, often outpacing or occurring in contrast to stable rates in older adults. This global phenomenon of “young-onset” CRC—now accounting for nearly one in ten new cases—has prompted intense investigation into its causes, with attention turning to contemporary lifestyle and environmental exposures that might accelerate colorectal tumorigenesis in younger cohorts. Accumulating evidence implicates perturbations of the gut microbiome as a key contributor to these epidemiologic shifts [3] . The human  \nintestinal microbiome, containing trillions of microbes and their collective genomes, sits atthe interface between environment and host and is increasingly recognized as an active modulator of CRC risk and behavior [3] .  \nMicrobiome–genome crosstalk in CRC has become a focal point of research, referring to the dynamic interactions by which gut microorganisms can influence host genetic pathways, induce mutations, and shape tumor biology [3] . Bacteria in the colon can produce metabolites and toxins that da","cbCaiedjYaJKQnGs","https://ap.wps.com/l/cbCaiedjYaJKQnGs","pdf",5366991,29,"English","# Introduction\n## Colorectal cancer burden and young-onset trends\n## Microbiome–genome crosstalk and the driver–passenger framework\n## pks+ E. coli colibactin: mutational signatures and driver selection","[{\"question\":\"What mutational signatures are linked to colibactin in colorectal cancer?\",\"answer\":\"Colibactin is associated with the SBS88 single-base substitution signature and the ID18 insertion/deletion signature, detected in colorectal cancer and even normal colonic crypts.\"},{\"question\":\"How does Fusobacterium nucleatum influence colorectal tumor behavior and treatment response?\",\"answer\":\"Fusobacterium nucleatum exerts clade-specific effects on tumor ecology and therapy response, with evidence for both chemoresistance and sensitization to anti-PD-1 in microsatellite stable (MSS) colorectal cancer.\"},{\"question\":\"What analysis approaches and constraints are described for detecting these signatures?\",\"answer\":\"The article outlines analytic standards for signature detection using whole-genome sequencing (WGS) or whole-exome sequencing (WES), single-sample fitting, and stated limits when mutation counts are low.\"}]","Microbiome–Genome Crosstalk in Colorectal Cancer - Colibactin Signatures and Fusobacterium nucleatum in Epidemiology, Driver Selection, and Translation | PDF",1790061919,73,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3192780fec28810dd696fdb17f0ee37.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/debe5457a76146b4cfe73f3d3ba900dc.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0630d5a9d03a508ca1fcae593f4b631.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9b3fd150dee6e2fe7d04be02678ee03.webp",980,692]